All In Biotech

Drug Trial Radar · NCT03737643

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,407 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,407

Actual

Start

Jan 4, 2019

Primary completion

Mar 17, 2025

Study completion Dec 23, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation; Myriad Genetic Laboratories, Inc.
First posted
Nov 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Conditions

  • Advanced Ovarian Cancer

Interventions

  • BevacizumabDrug

    Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.

  • DurvalumabDrug

    Durvalumab by intravenous infusion

  • OlaparibDrug

    Olaparib tablets

  • Placebo olaparibDrug

    Placebo tablets to match olaparib

  • Durvalumab placeboDrug

    Matching placebo for intravenous infusion

  • Carboplatin+PaclitaxelDrug

    Standard of care chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis SetTime frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
  2. Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months

Locations

214 sites in 20 countries. Site status is shown where the registry gives one.

  • Research Site

    Foothill Ranch, California

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    San Francisco, California

  • Research Site

    Tampa, Florida

  • Research Site

    Augusta, Georgia

  • Research Site

    Hinsdale, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Towson, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Springfield, Missouri

  • Research Site

    Middletown, New Jersey

  • Research Site

    Montvale, New Jersey

  • Research Site

    Albany, New York

  • Research Site

    New York, New York

  • Research Site

    Uniondale, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Dayton, Ohio

  • Research Site

    Hilliard, Ohio

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Lancaster, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Graz, Austria

  • Research Site

    Innsbruck, Austria

  • Research Site

    Linz, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Aalst, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Namur, Belgium

  • Research Site

    Ostend, Belgium

  • Research Site

    Sint-Niklaas, Belgium

  • Research Site

    Barretos, Brazil

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Fortaleza, Brazil

  • Research Site

    Londrina, Brazil

  • Research Site

    Porto Alegre, Brazil

Showing 40 of 214 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.